2
Registered trials
2
Recruiting
2
Unique sponsors
2
Unique IMPs
1
Commercial trials
Drug classes (ATC)
L
Oncology (ATC L)
1
—
ATC code not specified
1
Mechanism of action (INN-stem analysis)
Kinase inhibitor
1 substance
Checkpoint inhibitor (PD-1)
1 substance
Phase II:
1
Phase I (Other):
1
Phase II
1 trial-
RecruitingAGO Research GmbH CommercialLENVATINIB; PEMBROLIZUMAB
Phase I (Other)
1 trial-
RecruitingAmsterdam UMC Stichting AcademicIMP not specified
Sponsor activity
| Sponsor | Type | Trials | Phases | Recruiting |
|---|---|---|---|---|
| AGO Research GmbH | Commercial | 1 | Phase II | 1 |
| Amsterdam UMC Stichting | Academic | 1 | Phase I (Other) | 1 |
New trials by year
2025
1
2026
1